bioAffinity Technologies’ CEO, Maria Zannes, will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.
Presentation details are as follows:
Date: Tuesday, January 9, 2018
Time: 4:45 P.M. (PST)
Room: Yosemite Ballroom
Venue: Hilton San Francisco Union Square Hotel
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the
course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
